These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36239392)

  • 1. Impact of the number of cryopreserved CD34
    Partanen A; Turunen A; Silvennoinen R; Valtola J; Pyörälä M; Siitonen T; Sikiö A; Putkonen M; Sankelo M; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    J Clin Apher; 2023 Feb; 38(1):33-44. PubMed ID: 36239392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CD34
    Partanen A; Turunen A; Valtola J; Pyörälä M; Kuittinen O; Kuitunen H; Vasala K; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e428-e435. PubMed ID: 37684185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
    Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CD34
    Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
    Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
    Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.
    Abrahamsen JF; Wentzel-Larsen T; Bruserud O
    Cytotherapy; 2004; 6(4):356-62. PubMed ID: 16146888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A French single-center experience on allogeneic stem cell transplant cryopreservation during severe acute respiratory syndrome coronavirus 2 pandemic.
    Laroye C; Thilly N; Gauthier M; Luc A; Latger-Cannard V; Eschwege V; Bensoussan D; Pochon C; Campidelli A; Rubio MT; D'Aveni M; Decot V
    Cytotherapy; 2023 Aug; 25(8):877-884. PubMed ID: 37178096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lenalidomide-based induction therapy on the mobilization of CD34
    Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
    Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products.
    Sartor M; Antonenas V; Garvin F; Webb M; Bradstock KF
    Bone Marrow Transplant; 2005 Aug; 36(3):199-204. PubMed ID: 15937512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
    Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
    Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-thaw viability of cryopreserved hematopoietic progenitor cell grafts: does it matter?
    Vrhovac R; Perić Z; Jurenec S; Kardum-Skelin I; Jelić-Puskarić B; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):163-9. PubMed ID: 20432746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Putkonen M; Partanen A; Pyörälä M; Savolainen ER; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    Leuk Lymphoma; 2019 Feb; 60(2):453-461. PubMed ID: 30160591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.
    Roug AS; Hokland LB; Segel E; Nielsen K; Toft-Petersen M; Van Kooten Niekerk PB; Hokland P; Nederby L
    Cytotherapy; 2014 Mar; 16(3):392-401. PubMed ID: 24424268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.